Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
|Articles|September 2, 2007
- Pharmaceutical Technology-09-02-2007
- Volume 31
- Issue 9
Useful Contacts
Useful Contacts
Advertisement
Useful Contacts
Indian Drug Manufacturers' Association (IDMA)
Mumbai
tel. +91 22 2494 4624
Indian Pharmaceutical Association (IPA)
Mumbai
tel: +91 22 2667 0742
Indian Pharma Machinery Manufacturers' Association (IPMMA)
Mumbai
tel: +91 22 2578 6007
Organization of Pharmaceutical Producers of India (OPPI)
Mumbai,
Pharmaceuticals Export Promotion Council (Pharmexcil)
Hyderabad
tel: +91 40 2373 5462
For further information about the above companies, please email
Articles in this issue
about 19 years ago
Advances in Asymmetric Synthesisabout 19 years ago
A Call for FDA Inspectionsabout 19 years ago
CMOs Join Pharma Facility Swap Meetabout 19 years ago
Supplements to the PQRI Workshop Resultsabout 19 years ago
How to Gain Approval Overseasabout 19 years ago
Pharma Capsulesabout 19 years ago
Printing Digital Labelsabout 19 years ago
Enhancing Drug Safetyabout 19 years ago
The Challenges and Opportunities in ICH Q10Advertisement
Related to this article
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5